These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 23752409)

  • 1. What price affordable access?
    Nat Biotechnol; 2013 Jun; 31(6):467. PubMed ID: 23752409
    [No Abstract]   [Full Text] [Related]  

  • 2. When the price is right.
    Nat Biotechnol; 2006 May; 24(5):473. PubMed ID: 16680108
    [No Abstract]   [Full Text] [Related]  

  • 3. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
    Dalzell MD
    Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
    [No Abstract]   [Full Text] [Related]  

  • 5. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
    Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
    J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
    Dranitsaris G; Truter I; Lubbe MS
    Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Project data sphere to make cancer clinical trial data publicly available.
    Hede K
    J Natl Cancer Inst; 2013 Aug; 105(16):1159-60. PubMed ID: 23904505
    [No Abstract]   [Full Text] [Related]  

  • 13. Beware the cost-benefit analysis.
    Spence D
    BMJ; 2012 Jul; 345():e5040. PubMed ID: 22833630
    [No Abstract]   [Full Text] [Related]  

  • 14. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
    Refoios Camejo R; McGrath C; Herings R
    Health Policy; 2011 Apr; 100(1):18-24. PubMed ID: 20864202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular primary prevention: how high should we set the bar?
    Prasad V; Vandross A
    Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Norwegian drug policy--socioeconomically unprofitable, hostile to patients and to research].
    Jacobsen TK
    Tidsskr Nor Laegeforen; 1993 Oct; 113(26):3277-8. PubMed ID: 8236224
    [No Abstract]   [Full Text] [Related]  

  • 17. Oncology. Market indicators.
    Nat Rev Drug Discov; 2005 May; Suppl():S19. PubMed ID: 15962528
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.